Black Diamond Therapeutics, Inc. (BDTX)
BDTX moved a median of +0.26% 30 minutes after news, and -0.38% by the close. How BDTX actually reacts to news — the realized, point-in-time move the market made, measured across 192 labeled events over the last three years with zero look-ahead.
BDTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 44% | 192 |
| 30-min | +0.26% | 54% | 192 |
| 60-min | -0.38% | 45% | 192 |
| to close | -0.38% | 43% | 192 |
| Middle 50% of BDTX reactions | -2.26% to +1.80% |
|---|---|
| Median reaction (30-min) | +0.26% |
| Measured reactions | 192 |
Half of all Black Diamond Therapeutics, Inc. news events land between -2.26% and +1.80% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BDTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 14 | -0.46% | 43% | -1.80% |
| Rating reiterations | 46 | -0.28% | 44% | -0.89% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how BDTX ranks against every other measured name →
That’s how BDTX usually reacts — get an email when it moves on news →Email me when BDTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BDTX's baseline. Nothing else.
Recent BDTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | -0.47% | -2.33% | |
| Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.83% | +6.67% | |
| Form 10-Q Black Diamond Therapeuti For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.83% | +6.67% | |
| Form 8-K Black Diamond Therapeuti For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.83% | +6.67% | |
| Form 8-K Black Diamond Therapeuti For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +1.70% | +4.52% | |
| Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -2.33% | -24.25% | |
| Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations | Press release | GlobeNewswire | -2.33% | -24.25% | |
| Form 8-K Black Diamond Therapeuti For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -2.33% | -24.25% | |
| Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC | Press release | GlobeNewswire | -2.33% | +16.28% | |
| Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -4.72% | -1.80% | |
| Form 10-Q Black Diamond Therapeuti For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.72% | -1.80% | |
| Form 8-K Black Diamond Therapeuti For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -4.72% | -1.80% | |
| Form ARS Black Diamond Therapeuti For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.58% | +1.92% | |
| Form DEF 14A Black Diamond Therapeuti For: Jun 26 | SEC filing · Form DEF | SEC EDGAR | -0.58% | +1.92% | |
| Form DEFA14A Black Diamond Therapeuti | SEC filing · Form DEFA14A | SEC EDGAR | -0.58% | +1.92% | |
| Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting | Press release | GlobeNewswire | +0.33% | +3.96% | |
| Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +4.72% | +5.19% | |
| Form 10-K Black Diamond Therapeuti For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +4.72% | +5.19% | |
| Form 8-K Black Diamond Therapeuti For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | +4.72% | +5.19% | |
| Form S-8 Black Diamond Therapeuti | SEC filing · Form S-8 | SEC EDGAR | +4.72% | +5.19% | |
| Black Diamond Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.89% | -3.36% | |
| Form EFFECT Black Diamond Therapeuti | SEC filing · Form EFFECT | SEC EDGAR | -4.44% | +0.37% | |
| Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM | Press release | GlobeNewswire | -14.88% | -19.94% | |
| Form 8-K Black Diamond Therapeuti For: Dec 03 | SEC filing · Form 8-K | SEC EDGAR | -14.88% | -19.94% | |
| Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update | Press release | GlobeNewswire | -14.88% | -19.94% | |
| Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.77% | +2.05% | |
| Black Diamond Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.25% | -1.02% | |
| Form 10-Q Black Diamond Therapeuti For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.77% | +2.05% | |
| Form 8-K Black Diamond Therapeuti For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.77% | +2.05% | |
| Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -5.58% | -9.52% | |
| Form 10-Q Black Diamond Therapeuti For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.58% | -9.52% | |
| Form 8-K Black Diamond Therapeuti For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -5.58% | -9.52% | |
| Form 8-K Black Diamond Therapeuti For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +1.28% | -1.28% | |
| Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -2.94% | +10.29% | |
| Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | +1.05% | |
| Form 10-Q Black Diamond Therapeuti For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +1.05% | |
| Form 8-K Black Diamond Therapeuti For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.05% | |
| Form ARS Black Diamond Therapeuti For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.70% | +6.43% | |
| Form DEF 14A Black Diamond Therapeuti For: Jun 12 | SEC filing · Form DEF | SEC EDGAR | +0.70% | +6.43% | |
| Form DEFA14A Black Diamond Therapeuti | SEC filing · Form DEFA14A | SEC EDGAR | +0.70% | +6.43% | |
| Black Diamond Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -2.18% | -1.90% | |
| Form 8-K Black Diamond Therapeuti For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | +11.86% | -27.12% | |
| Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy | Press release | GlobeNewswire | +11.86% | -27.12% | |
| Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.54% | +2.17% | |
| Form 10-K Black Diamond Therapeuti For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.54% | +2.17% | |
| Form 8-K Black Diamond Therapeuti For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | +2.17% | |
| Form S-8 Black Diamond Therapeuti | SEC filing · Form S-8 | SEC EDGAR | -0.54% | +2.17% | |
| Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +4.79% | +3.83% | |
| Form 10-Q Black Diamond Therapeuti For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.79% | +3.83% | |
| Form 8-K Black Diamond Therapeuti For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | +4.79% | +3.83% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BDTX section they belong to.
Where else BDTX is measured.
BDTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Black Diamond Therapeutics, Inc.'s median reaction calculated?
Every labeled BDTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 192 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 54% of BDTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BDTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.